Prima

Breast and Ovarian Cancer

Book Test Now
Prima

Hereditary Cancer

Introduction

Single gene tests offered within Prima

  • An estimated 14.5 lakh people are living with cancer in India
  • Over 7 lakh new cases being registered every year
  • Over 8.8 lakh deaths will be due to cancer by 2020
  • Cancers of breast, lung and cervix will top the list

* National Cancer Registry Program - ICMR

Prima

MedGenome’s comprehensive offering of the most advanced genetic and molecular tests for cancer management

Advanced testing techniques in Prima

Advanced testing techniques in Prima

Single gene tests offered within Prima

Single gene tests o ered within Prima

Gene Panel tests offered within Prima

Gene Panel tests offered within Prima

How Molecular and Genetic Testing helps?

  • Ability to sub-classify the type of cancer
  • Disease prognostication (assessment of survival and response to treatment)
  • Theranostic Value (Finding the best targeted drugs - alleviating unnecessary chemotherapy and radiation)
  • Hereditary cancer risk assessment
The latest NCCN guidelines for oncology practice (2017) has provided clear recommendations for BRCA testing in hereditary breast and ovarian cancers.
NCCN guidelines

Facts - Breast Cancer

  • 75% patients who have BRCA1 mutation and breast cancer will be triple negative
  • 20% patients with BRCA2 mutation and breast cancer will be triple negative
  • Hence patients with triple negative breast cancer should consider familial BRCA testing if they:
  1. Have a relative with ovarian or breast cancer
  2. Are diagnosed with breast cancer younger than 60 yrs of age
  3. Have suspicious pathology or radiologic test results

BRCA positive individuals have 54-84% higher risk of developing cancers

Facts - Breast Cancer

Facts - Ovarian Cancer

Burden of Disease

Burden of Disease
Burden of Disease

Breast Cancer is the leading cause of disability adjusted life years (DALYs) in woman globally (WHO, the Global Burden of Cancer 2013; JAMA Oncology 2015 Jul, Mohsen Naghavi) Ovarian cancer is the seventh most common cancer in women worldwide (occupies the 18th position as the most common cancer)

Statistics - India Breast Cancer

In India, the average of the yearly statistical report on breast cancer suggests, Incidence: 144,937 and Mortality: 70,218. In newly diagnosed cases of breast cancer, approximately for every 2 women in India, 5-6 women in US and 4 women in China, 1 woman is dying of it.

Ovarian Cancer

  • Ovarian cancer is the third leading site of cancer among women, trailing behind cervix and breast cancer.
  • The age-adjusted incidence rates of ovarian cancer vary between 5.4 and 8.0 per 100,000 population in different parts of the country.

How do hereditary cancers differ from sporadic one?

A small percentage of all breast cancers run in the families and these,

  • Tend to develop earlier in life than sporadic cases
  • Tend to be more aggressive
  • Primary tumors are more likely to develop bilaterally
  • Many breast cancers are triple negative, while ovarian are BRCA positive
  • Associated with mucinous or apocrine histopathologies

Breast Cancer Genetics

Contribution of known genes to familial aggregation of breast cancer

Contribution of known genes to familial aggregation of breast cancer

The impact of genome-wide association studies (GWAS) on the familial component of breast cancer

2007

Advanced testing techniques in Prima

2013

Single gene tests o ered within Prima

Eccles et al 2013. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 15:R92.

Ovarian Cancer Genetics

Hereditary Ovarian Cancer

Ovarian cancer genetics

Theranostics in Breast Cancer

Breast cancer subtypes and their overlapping molecular targets

Theranostics in Breast Cancer

Ovarian Cancer

25 molecular targets across 41 ovarian cancer phase II, III studies (as of 7/8/2016)

Androgen receptor FLK1 PDGFR
Aromatase FR-alpha SRC
BCR/ABL* (BRCA) HIF1-alpha TOP1
Cancer stemness patways IL2R TOP2
CDK4 KDR tubulin
CDK6 NADPH VEGFR
CSK PD-1 Wee1
FGFR PDGFR

Prima solution for Breast and Ovarian Cancer

Comprehensive Hereditary Cancer Panel

Tests for mutations in genes responsible for multiple hereditary cancers as well as other genetic syndromes that may be present with benign or malignant tumors.

Somatic Mutation Panel

Guides the doctors to understand the genetic profile of the tumor which would assist them in establishing the diagnosis, and define the course of clinical action. It also helps them know the response of specific therapy.

Breast Prognostic/predictive IHC1 panel (ANY ONE OF - ER, PR, Her2/neu, MIB-1/ Ki67)

Breast Prognostic/predictive IHC2 panel (ER, PR)

Breast Prognostic/predictive IHC3 panel (ER, PR, Her2/neu)

Breast Prognostic/predictive IHC4 panel (ER, PR, Her2/neu,MIB-1/Ki67)

Breast Cancer - NGS Theranostic Panel (Hot Spot)

ERBB2, AKT1, PIK3CA & PTEN

Prima BRCA Testing

MedGenome BRCA Testing will guide doctors to define a course of clinical action by providing disease relevant personalised genetic information

  • BRCA testing involves whole gene sequencing of the BRCA1 and BRCA2 genes
  • MedGenome Offers BRCA1/2 analysis as a standalone assay or part of a larger panel
  • Comprehensive BRCA1/2 testing includes gene sequencing and deletion/duplication analysis by MLPA (for large rearrangements)
Breast Cancer

Benefits of testing with Prima

  • Comprehensive gene range covers wider spectrum of cancer types
  • Targets 18 cancers including benign or malignant tumors
  • Helps identify familial cancer risks based on mutations in specific genes
  • Multiple gene analysis offers a wider risk assessment of cancer and thus is cost effective

Sample Requirements

The sources of the sample can be the following depending on the test

  1. Fresh frozen tumor tissue (3-4mm sections)
  2. FFPE tumor tissue (3-4mm sections containing upto 70% of the tumor content as verified by the pathologist)
  3. Blood (3-5ml)

Turnaround Time

Time taken for the generating a clinical report will be maximum of 4 weeks for NGS

In case where the sample quality is poor (sample which fails our QA/QC), the TAT will get prolonged.

New batch of sample needs to be submitted for sequencing and analysis.

Geknow Hub

Geknow Hub

MedGenome’s commitment to sharing knowledge related to Genes and Genomics

As a leader in providing genomics testing solutions in India, MedGenome recognizes that it’s imperative for a clinician to be enabled with the most accurate information and the deepest insights for providing better treatment outcomes. Through our GeKNOW hub, we give you the best and latest rich sets of information, you can learn about, and capitalize on the tremendous possibilities that our solutions can help you with.

Free Genetic Counselling

Free Genetic Counselling

Actia offers all your patients FREE pre & post-test genetic counselling with our expert and certified genetic counsellors.

Best available support for your patients and families via

  • Latest technologies
  • Helpful customer service
  • Clear result interpretation
  • Counselling sessions with our Genetic Counsellors
Dial 1800 103 3691
diagnostics@medgenome.com

Our representative will get in touch with you within 24 hours to help you with the registration. You can start prescribing the test right away and help your patients gain clarity about their genetic health.

Talk with one of our Genetic experts for free today

Our certified genetic specialists are available right now to discuss your queries before, during and after screenings.

Name field is not valid
City field is not valid
Email field is not valid
Phone field is not valid